BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Lenacapavir (Yeztugo) readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Lenacapavir (Yeztugo)\, from ClinicalTria
 ls.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07210125-11049@assetmemo.bio
DTSTAMP:20261121T005022Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Lenacapavir (Yeztugo): Phase 4 readout est. (NCT07210125)
DESCRIPTION:Lenacapavir (Yeztugo)\, phase 4\, HIV.\nStudy: Implementation a
 nd Deliver of Lenacapavir for PrEP in a Community Pharmacy Setting\nEstima
 ted primary completion: 31 March 2027. This is a ClinicalTrials.gov estima
 te\, not a confirmed readout date\, and it can move.\nDrug page: https://a
 ssetmemo.bio/drug/lenacapavir-yeztugo#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT07210125
URL:https://assetmemo.bio/drug/lenacapavir-yeztugo#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07335289-11049@assetmemo.bio
DTSTAMP:20261121T005022Z
DTSTART;VALUE=DATE:20270701
DTEND;VALUE=DATE:20270702
SUMMARY:Lenacapavir (Yeztugo): Phase na readout est. (NCT07335289)
DESCRIPTION:Lenacapavir (Yeztugo)\, phase na\, HIV.\nStudy: PrEP4U: Assessi
 ng the Effectiveness of Integrated Same-Day Lenacapavir Initiation and Fol
 low-up Choice on PrEP Persistence\nEstimated primary completion: 1 July 20
 27. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\,
  and it can move.\nDrug page: https://assetmemo.bio/drug/lenacapavir-yeztu
 go#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0
 7335289
URL:https://assetmemo.bio/drug/lenacapavir-yeztugo#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07218211-11049@assetmemo.bio
DTSTAMP:20261121T005022Z
DTSTART;VALUE=DATE:20270731
DTEND;VALUE=DATE:20270801
SUMMARY:Lenacapavir (Yeztugo): Phase 4 readout est. (NCT07218211)
DESCRIPTION:Lenacapavir (Yeztugo)\, phase 4\, HIV.\nStudy: Enhancing PrEP U
 ptake and Retention Among Latine TGW and GBM in the South Using Long-Actin
 g Injectable PrEP\nEstimated primary completion: 31 July 2027. This is a C
 linicalTrials.gov estimate\, not a confirmed readout date\, and it can mov
 e.\nDrug page: https://assetmemo.bio/drug/lenacapavir-yeztugo#upcoming-eve
 nts\nRegistry record: https://clinicaltrials.gov/study/NCT07218211
URL:https://assetmemo.bio/drug/lenacapavir-yeztugo#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07047716-11049@assetmemo.bio
DTSTAMP:20261121T005022Z
DTSTART;VALUE=DATE:20280930
DTEND;VALUE=DATE:20281001
SUMMARY:Lenacapavir (Yeztugo): Phase 3 readout est. (NCT07047716)
DESCRIPTION:Lenacapavir (Yeztugo)\, phase 3\, HIV.\nStudy: Study of Lenacap
 avir as a Once-Yearly Injection for HIV Pre-exposure Prophylaxis (PrEP)\nE
 stimated primary completion: September 2028. This is a ClinicalTrials.gov 
 estimate\, not a confirmed readout date\, and it can move.\nDrug page: htt
 ps://assetmemo.bio/drug/lenacapavir-yeztugo#upcoming-events\nRegistry reco
 rd: https://clinicaltrials.gov/study/NCT07047716
URL:https://assetmemo.bio/drug/lenacapavir-yeztugo#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07497594-11049@assetmemo.bio
DTSTAMP:20261121T005022Z
DTSTART;VALUE=DATE:20290228
DTEND;VALUE=DATE:20290301
SUMMARY:Lenacapavir (Yeztugo): Phase na readout est. (NCT07497594)
DESCRIPTION:Lenacapavir (Yeztugo)\, phase na\, HIV.\nStudy: ImPrEP LEN Bras
 il: Twice-Yearly Lenacapavir for HIV Prevention\nEstimated primary complet
 ion: February 2029. This is a ClinicalTrials.gov estimate\, not a confirme
 d readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/l
 enacapavir-yeztugo#upcoming-events\nRegistry record: https://clinicaltrial
 s.gov/study/NCT07497594
URL:https://assetmemo.bio/drug/lenacapavir-yeztugo#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
